Unlocking the Power of the Nervous System Is a $100B Opportunity

This estimated $100B medical industry is inviting early investors to get in now before a planned Nasdaq listing............................................................................................................................................ [email-img]( Few can imagine traveling with a paper map anymore. Well, that's the equivalent of today's technology when it comes to treating the human nervous system – but this estimated [$100B medical industry may be about to get its "GPS" moment.]( Nasdaq Listing: Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders like never before. And they're inviting early investors to get in now before a planned Nasdaq listing. Potential Industry Disruption: While today's solutions are similar in size to a suitcase, in non-clinical settings Autonomix has achieved thousands of times more sensitive detection and analysis with the same microelectronics found in the Apple Watch – powered by a proprietary 1x2-millimeter microchip. Proven Winners: Their team of scientists has a successful track record. And now, they see a potentially untapped $100B market opportunity like no one else can. [See how you can invest in Autonomix before their planned Nasdaq listing.]( Disclosure: This is a paid advertisement for Autonomix's Regulation A+ Offering. Please read the offering circular at [invest.autonomix.com]( --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for Autonomix(NASDAQ:ATX) from Strike Point. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1,000. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Autonomix(NASDAQ:ATX) or Strike Point. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Autonomix(NASDAQ:ATX) on Autonomix website for additional information about the relationship between Strike Point and Autonomix(NASDAQ:ATX). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com